NIH NIAID Clinical Research Network on Antimicrobial Resistance (AMR) – RFA-AI-27-005

The National Institute of Allergy and Infectious Diseases (NIAID) is accepting applications for the Clinical Research Network on Antimicrobial Resistance (AMR) under RFA-AI-27-005. The network will design, implement, and manage clinical research addressing pivotal antimicrobial-resistance questions through four integrated centers: a Scientific Leadership Center, Clinical Operations Center, Laboratory Center, and Statistics and Data Coordination Center.

NIAID intends to commit $18 million in FY 2027 for one award. Application budgets are not expected to exceed $12 million in direct costs per year, and the project period must be seven years. No cost sharing is required.

Eligible domestic applicants include higher education institutions, nonprofits, for-profit organizations including small businesses, state and local governments, Tribal governments and organizations, independent school districts, and other listed U.S. entities. Foreign organizations are not eligible. Applicant organizations must maintain SAM/UEI, Grants.gov, and eRA Commons registrations; PD/PIs must have eRA Commons accounts linked to ORCID.

Deadline: Applications are due November 10, 2026 at 5:00 PM local time of the applicant organization. The earliest submission date is October 10, 2026.

Atlas rates the Nonagon N9+ fit at 54/100. A legitimate role could include protocol-defined guided remote physical examinations, vitals, telehealth-enabled follow-up, or objective clinical data capture where those functions directly support an approved AMR clinical trial or study. The NOFO does not specifically fund telehealth and N9+ should not be presented as an AMR diagnostic or treatment. Dr. Miltie is legally eligible as a for-profit organization but is not treated as prime-ready without the required large-scale clinical-research network, scientific leadership, laboratory, operations, biostatistics/data, regulatory, site-management, and AMR trial capacity.